Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Shares Gap Down After Analyst Downgrade

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) shares gapped down before the market opened on Tuesday after Zacks Research downgraded the stock from a strong-buy rating to a hold rating. The stock had previously closed at $26.35, but opened at $23.95. Fresenius Medical Care AG & Co. KGaA shares last traded at $23.8210, with a volume of 503,964 shares traded.

A number of other equities analysts have also commented on FMS. UBS Group lowered Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a research note on Wednesday, October 15th. Morgan Stanley restated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, August 12th. Weiss Ratings upgraded Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. Wall Street Zen upgraded Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 25th. Finally, Bank of America lowered Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a research report on Wednesday, October 15th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus price target of $30.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of FMS. Wayfinding Financial LLC acquired a new position in Fresenius Medical Care AG & Co. KGaA in the first quarter valued at $25,000. Brooklyn Investment Group grew its holdings in Fresenius Medical Care AG & Co. KGaA by 424.5% during the 1st quarter. Brooklyn Investment Group now owns 1,285 shares of the company’s stock worth $32,000 after acquiring an additional 1,040 shares during the period. TD Waterhouse Canada Inc. bought a new position in shares of Fresenius Medical Care AG & Co. KGaA in the 2nd quarter worth about $36,000. Atlantic Union Bankshares Corp bought a new position in shares of Fresenius Medical Care AG & Co. KGaA in the 2nd quarter worth about $43,000. Finally, Hantz Financial Services Inc. lifted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 568.5% in the 2nd quarter. Hantz Financial Services Inc. now owns 2,079 shares of the company’s stock valued at $59,000 after purchasing an additional 1,768 shares during the period. 8.37% of the stock is owned by institutional investors and hedge funds.

Fresenius Medical Care AG & Co. KGaA Price Performance

The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.08 and a current ratio of 1.44. The business has a 50 day moving average price of $26.03 and a 200-day moving average price of $26.57. The company has a market capitalization of $14.28 billion, a price-to-earnings ratio of 19.95, a P/E/G ratio of 0.64 and a beta of 0.90.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its earnings results on Tuesday, November 4th. The company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.05. Fresenius Medical Care AG & Co. KGaA had a return on equity of 6.75% and a net margin of 3.39%.The business had revenue of $5.63 billion during the quarter, compared to the consensus estimate of $4.72 billion. Research analysts predict that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current fiscal year.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.